EGFR and non-small cell lung carcinoma: Our retrospective analysis demonstrated a s significantly longer mOS in patients with EGFR-positive NSCLC who received EGFR-TKI treatment (regardless of the treatment sequence) than in those who did not (28.9 vs. 7.4 months, P<0.001).